CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Published:2016-06-30 Issue:26 Volume:127 Page:3360-3368
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Berenson James R.¹,Cartmell Alan²,Bessudo Alberto³,Lyons Roger M.⁴,Harb Wael⁵,Tzachanis Dimitrios⁶,Agajanian Richy⁷,Boccia Ralph⁸,Coleman Morton⁹,Moss Robert A.¹⁰,Rifkin Robert M.¹¹,Patel Priti¹²,Dixon Sandra¹²,Ou Ying¹²,Anderl Janet¹²,Aggarwal Sanjay¹²,Berdeja Jesus G.¹³

Affiliation:

1. Institute for Myeloma and Bone Cancer Research, West Hollywood, CA;

2. Comprehensive Blood and Cancer Center, Bakersfield, CA;

3. Cancer Care Associates for Research and Excellence, Encinitas, CA;

4. US Oncology Research and Cancer Care Centers of South Texas, San Antonio, TX;

5. Horizon Oncology Center, Lafayette, IN;

6. Cedars-Sinai Medical Center, Los Angeles, CA;

7. The Oncology Institute of Hope and Innovation, Downey, CA;

8. Center for Cancer and Blood Disorders, Bethesda, MD;

9. Department of Hematology/Oncology, Weill Cornell Medical College, Clinical Research Alliance, New Hyde Park, NY;

10. Robert A. Moss Medical Oncology and Hematology, Fountain Valley, CA;

11. US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO;

12. Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA; and

13. Sarah Cannon Research Institute, Nashville, TN

Abstract

Key PointsThe CHAMPION-1 study is the first clinical trial to investigate carfilzomib on a once-weekly dosing schedule with dexamethasone. Once-weekly carfilzomib (30-minute infusion; 20 and 70 mg/m2) with dexamethasone is feasible and effective in relapsed/refractory MM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/26/3360/1394024/3360.pdf

Reference27 articles.

1. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.;Petrucci;Br J Haematol,2013

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153].;Kumar;Leukemia,2012

3. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.;Siegel;Blood,2012

4. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.;Stewart;N Engl J Med,2015

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone;Targeted Oncology;2024-04-20

2. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study);Future Oncology;2024-02-29

3. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL);American Journal of Hematology;2023-06-19

4. Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients;Haematologica;2023-04-27

5. Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome;Clinical Pharmacokinetics;2023-04-18